# A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

> **NCT06190951** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 151 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** cemiplimab
- **DRUG:** Fixed Dose Combination (FDC) cemiplimab+fianlimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06190951
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2026-11-02
- **Final completion:** 2030-12-09
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190951, "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06190951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*